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Carcinoembryonic antigen (CEA) is the only blood based protein biomarker at present, used for 
preoperative screening of advanced colorectal cancer (CRC) patients to determine the appropriate 
curative treatments and post-surveillance screening for tumour recurrence. Current diagnostics for 
CRC detection have several limitations and development of a highly sensitive, specific and rapid 
diagnostic device is required. The majority of such devices developed to date are antibody-based and 
suffer from shortcomings including multimeric binding, cost and difficulties in mass production. To 
circumvent antibody-derived limitations, the present study focused on the development of Affimer 
proteins as a novel alternative binding reagent for CEA detection. Here, we describe the selection, 
from a phage display library, of Affimers specific to CEA protein. Characterization of three anti-CEA 
Affimers reveal that these bind specifically and selectively to protein epitopes of CEA from cell culture 
lysate and on fixed cells. Kinetic binding analysis by SPR show that the Affimers bind to CEA with high 
affinity and within the nM range. Therefore, they have substantial potential for used as novel affinity 
reagents in diagnostic imaging, targeted CRC therapy, affinity purification and biosensor applications.
Colorectal cancer (CRC) is the fourth leading cause of cancer-related death and the third most commonly diag-
nosed malignancy  worldwide1. Despite improvements in cancer treatment, advanced technologies in cancer 
diagnostics and augmentation of cancer awareness, the incidence and mortality rates of CRC still remain high. 
Late CRC diagnosis is associated with high morbidity and mortality rates. Hence, new strategies that can acceler-
ate current diagnostic modalities in CRC diagnosis are crucial.
Carcinoembryonic antigen (CEA) is the first tumour associated antigen that was initially discovered in 1965 
to be specific for colorectal cancer (CRC) and was later found to be abundant in many malignant  tumours2. CEA, 
also known as carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) or CD66e, is the only 
blood based protein biomarker at present that is clinically approved as a prognostic biomarker for determining 
the treatment regime and as a surveillance biomarker for monitoring tumour recurrence in post-operative CRC 
 patients3,4. CEA is predominantly overexpressed on the cell surface of tumours derived from epithelial origin 
including colorectal, lung, gastric, pancreatic and breast cancers and is also secreted into the blood  stream5,6. 
High concentrations of CEA in the blood serum are commonly found in the advanced stages of CRC (stage II 
and III) and increased expression after surgery is an indicator of tumour recurrence or metastasis to the liver 
or  lung4,6. Circulating CEA in the blood plasma is the prime target in enzyme-linked immunosorbent assay 
(ELISA) tests to determine the level of CEA and in assessment of cancer progression. CEA is a highly N-linked 
glycosylated oncofoetal antigen comprised of an N-terminal domain, three highly conserved repeat domains 
and a glycophosphatidylinositol (GPI)-membrane anchored hydrophobic C-terminal  domain5.
For several decades, antibodies have been used as excellent natural binding reagents in therapeutic and diag-
nostic applications. They are known for their high specificity and sensitivity, strong affinity towards their target 
and long serum half-life7,8. The latter is a crucial feature of targeted drug carriers and biotherapeutic agents. 
However, their complex protein structure, batch-to-batch variability, expensive and slow production, complex 
chemical modification for oriented immobilisation in immunoassay applications and poor tissue penetration due 
to their size (~ 150 KDa)9 have rendered them of limited use in some biomedical and bioanalytical applications. 
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These drawbacks have driven the generation of non-immunoglobulin protein scaffolds as alternative binding 
reagents such as  Affibodies10, FN3  domains11,  DARPins12,  Anticalins13 and  Affimers14.
Affimer proteins show comparable applicability to antibodies. They are engineered protein scaffolds (12–14 
KDa) originally derived from a cystatin consensus  sequence15 or human stefin  A16. The former is commercially 
known as Affimer type II, and was used in this study, whilst, the latter is known as Affimer type I. These mono-
clonal reagents are small, monomeric, lack disulphide bonds and glycosylation sites and are  thermostable14,15. 
The use of Affimers as versatile affinity reagents has been reported in broad applications targeting more than 350 
different biological  targets14 including in the modulation of protein function and protein–protein  interaction17–20, 
directing formation of magnetic  nanoparticles21 and development of highly sensitive and specific  biosensors22–25. 
Although there have been several reports on the development of anti-CEA reagents from recombinant antibody 
 technology26,27, based on the promising potential of Affimers as alternative affinity reagents, we postulated that 
generation of CEA binding Affimers could facilitate the acceleration of diagnostics and treatment of CRC and 
other cancers.
In this study, we describe the selection of Affimers specific to CEA protein screened from an Affimer phage 
display library. Each displayed Affimer comprises a cystatin-derived scaffold with two variable regions, each 
containing nine random amino acids, excluding cysteine, in each variable region. Through characterisation 
studies, we have demonstrated that the anti-CEA Affimers bind specifically and selectively to protein epitopes 
of CEA within complex protein matrices, such as cell lysates and in fixed cells. They recognise multiple forms 
of functional CEA including the fully glycosylated native form as well as incompletely glycosylated and degly-
cosylated forms. Kinetic binding analysis by SPR has shown that the Affimers bind to CEA with high affinities 
within the nM range. Therefore, they have potential as alternative bioreceptors in bioanalytical applications for 
CEA, notably in colorectal cancer.
Results and discussion
Phage display selection of Affimer proteins specific to CEA. Affimers specific to CEA were identi-
fied from the phage display library constructed by the BioScreening Technology Group (BSTG), University of 
Leeds, UK. After three biopanning rounds, 48 randomly picked positive Affimer clones were evaluated for their 
binding ability to CEA by phage ELISA (Fig. 1A) and subsequently their DNA was sent for DNA sequencing to 
allow analysis of the binding loop sequences. Results revealed 3 unique CEA binders and amino acid analysis 
using ProtParam software suggested that the theoretical pI values of the Affimers were within the neutral range 
(pI ~ 7). CEA-Affimer-I and II contained 9 distinct amino acid residues in each variable region which are based 
on the design of the scaffold library reported by Tiede and co-workers15. However, CEA-Affimer-III has an extra 
amino acid residue in the variable region 2. CEA-Affimers II and III yielded 8.3 and 6.27 mg of protein from a 
50 ml culture whilst CEA-Affimer-I only yielded 0.24 mg of purified protein. The purity and molecular mass of 
the Affimer proteins was determined using liquid chromatography mass spectrometry (LC–MS) analysis and 
results showed that all proteins were pure and the molecular masses of CEA-Affimer-I, II and III were 12,676, 12, 
499 and 12,612 Da, respectively (Fig. 1B–D). Dimers were observed with CEA-Affimer-I and III which may have 
resulted from the formation of disulphide bond between thiol groups located at the C-terminus.
Specificity of binding of Affimers on CEA-expressing cells. Phenotypically, LoVo cells are known to 
over-express CEA on their plasma  membranes28,29. To determine the specificity of Affimer binding to CEA on 
fixed LoVo cells, direct fluorescent staining was performed by using biotinylated anti-CEA Affimers as the pri-
mary reagent and streptavidin conjugated DyLight 488 as the detection reagent. Immunofluorescence staining 
using monoclonal anti-CEA and Alexa Fluor 488 conjugated secondary antibodies was included as comparison. 
Localization of CEA was observed on the surface of LoVo cells which is consistent with CEA being a membrane–
anchored glycoprotein (Fig. 2A–C) but no staining was found on HEK 293 cells (Fig. 2E–H). Interestingly, the 
Affimers generally showed higher intensity of staining with a wider distribution compared to immunostaining 
(Fig. 2D). These findings indicated that CEA binding Affimers have better sensitivity and specificity than the 
corresponding antibody. This could be due to their being physically smaller than antibodies (~ 3 nm for Affimer 
vs. ~ 14 nm for IgG) facilitating better penetration into fixed  cells14,30.
Specificity of Affimer binding to soluble CEA. Apart from being overexpressed on colorectal cancer 
cells cell membranes, CEA is also secreted in soluble form into the blood stream which is predominant form 
of CEA used clinically to determine the staging of colorectal cancer and to monitor tumour recurrence. To 
investigate the ability of Affimers to bind specifically to native CEA in a complex protein mixture, pull-down 
assays were performed against the cell lysates and soluble CEA present in the culture medium. Purified Affimers 
were immobilized onto  Ni2+-NTA resin which was subsequently used to pull-down CEA from protein mixtures. 
Results from SDS-PAGE analysis demonstrated that all anti-CEA Affimers specifically pulled-down fully-glyco-
sylated CEA from the cell lysates and soluble CEA secreted into the media as shown by a single band detected 
around 200 KDa (Supplementary Fig. S1). An identical band was seen in reference CEA, commercially obtained 
from Abcam. By contrast, no band was detected from the cell lysates of HEK 293 cells, which was used as a nega-
tive control, except a single band at 13 KDa that corresponded to Affimer protein. Similarly, only a single band 
at Affimer size was observed when using yeast SUMO-10 binder as the control Affimer ligand (Supplementary 
Fig. S1). Immunoblotting of the corresponding pull-down complex using anti-CEA and anti-His6 tag antibodies 
further corroborated that the bands detected at 200 KDa and 13 KDa do indeed represent the CEA and Affimer 
proteins respectively, as shown in Fig. 3 and Supplementary Fig. S2. Taken together, these findings demonstrated 
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Recognition of CEA protein epitopes by Affimers. CEA is a highly N-linked glycosylated protein 
comprising 60% oligosaccharide which is added during post-translational modification. Epitope mapping stud-
ies of CEA protein using monoclonal antibodies indicated that there are two types of epitope present on CEA; 
protein and sugar  epitopes31,32. To distinguish whether CEA binding Affimers interacted with sugar or protein 
epitopes, deglycosylation of CEA protein via enzymatic PNGase F treatment was conducted. The same pull-
down assay as previous was performed but this time challenged against deglycosylated CEA. RNase B protein 
was included as a positive control for PNGase F treatment and a non-specific target for CEA-Affimers. Yeast 
SUMO-10 binder was used as control Affimer. The pull-down complexes were separated by reducing SDS-PAGE 
and the extent of Affimer binding was investigated by immunoblotting. Results showed that the molecular 
weight of CEA was reduced to around 100 KDa after deglycosylation and all anti-CEA Affimers still bound 
specifically to this form (Fig. 4A). No binding was observed to deglycosylated RNase B and from the control 
Figure 1.  Phage ELISA of Affimer clones and LC–MS analysis of the purified CEA-Affimer protein. (A) Forty 
eight positive clones were incubated in wells coated with biotinylated CEA (blue bars) whilst biotinylated targets 
were omitted in the negative control wells (red bars); (B–D) the mass spectra of the purified CEA-Affimer I to 
III displaying the monomer and dimer peaks.
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Affimer. Additionally, an immunoblot probed using anti-His6 tag antibody confirmed the presence of Affimers 
in the pull-down complex as shown in Fig. 4B and Supplementary Fig. S3. Based on these findings, it was clear 
that CEA binding Affimers recognized protein epitopes of CEA and deglycosylation did not affect the binding 
interaction of anti-CEA Affimers. However, further work needs to be done to distinguish which protein epitopes 
do the anti-CEA Affimers bind to, as there are seven protein domains within CEA.
Figure 2.  Cell binding and selectivity of anti-CEA Affimers on LoVo cells in comparison to monoclonal 
antibody. (A) to (C) show affinity-fluorescence staining of CEA binding Affimer I, II and III on LoVo cells 
compared to immunofluorescence staining using anti-CEA monoclonal antibody (D). No binding is present on 
corresponding HEK 293 negative control cells (E to H).
Figure 3.  Immunoblotting of Affimer precipitated CEA. Monoclonal anti-CEA and anti-His6 tag antibodies 
were used to probe (A) the CEA protein and (B) Affimers, respectively from the pull-down complex. Yeast 
SUMO-10 binder was used as a control Affimer. Commercial CEA from Abcam was used as positive control 
and cell lysates from HEK 293 as negative control. LoVo M and C are samples from medium and cell lysates, 
respectively. Full-length blots are presented in Supplementary Fig. S3.
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Kinetic binding analysis using SPR. To determine the kinetics of binding between Affimers and CEA, 
surface plasmon resonance (SPR) analysis was performed. A low-density surface was generated by immobiliz-
ing biotinylated anti-CEA Affimers as bioreceptors to give 270 RU (Supplementary Fig. S4) and the interaction 
with series of CEA concentrations (7.8125 nM to 1 µM) (Fig. 5A–C) was evaluated at high flow-rate (50 µl/
min) to eliminate the mass transport limiting factor. The kinetic parameters were extracted from the global 
fitting of experimental data using a 1:1 Langmuir interaction model (Fig. 5D–F). Small χ2 value ranging from 
0.066 to 1.94 indicated a very close-fit between the fitted curves (Fig. 5D–F, red lines) and the experimental 
curves (Fig. 5D–F, black lines). CEA-Affimer-I and II had similar association and dissociation rate constants. 
By comparison, CEA-Affimer-III had slower association and dissociation rate constants. Association (ka), dis-
sociation (kd) and equilibrium (KD) constants are given in Table 1. CEA-Affimer-I had the highest affinity with 
KD = 6.46 ± 1.38  nM, whilst CEA-Affimer-II and III showed moderate affinities with KD = 15.3 ± 0.37  nM and 
34.4 ± 16 nM, respectively.
Previous studies have investigated the relationship between specificity and affinity of antibody and protein 
interactions. They concluded that the antibody paratopes are substantially enriched with amino acid residues 
containing aromatic side chain (tyrosine, tryptophan and phenylalanine) and surrounded by short-chain hydro-
philic side chains (aspartate, asparagine, serine, threonine, and glycine) with the latter playing an important role 
in attaining the conformation that enables high affinity  binding33,34. Interestingly, these amino acid residues (all 
except threonine) are present in each variable region of all anti CEA-Affimers with approximately 44% frequency 
(8 of 18 amino acids) within their variable regions. The anti- CEA-Affimers we selected exhibited high affinity 
constants within the nM range from 6.46 to 34.4 nM, also in agreement with this notion. Accordingly, Sha et al.35 
Figure 4.  Immunoblotting of Affimer precipitated deglycosylated CEA. Immunoblotting of affinity-
precipitation using CEA binding Affimers as ligand to pull-down deglycosylated CEA (n = 2). Monoclonal 
anti-CEA and anti-His6 tag antibodies were used to probe the pulled-down (A) deglycosylated CEA and (B) 
Affimers, respectively. Yeast SUMO-10 binder was used as a control Affimer and RNase B was used as non-
specific analyte. Digested CEA was used as a reference to the pulled-down CEA in blotting. Full-length blot of 
Fig. 4B is presented in Supplementary Fig. S3.
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postulated that this phenomenon occurs in the majority of synthetic binding proteins including Nanobodies and 
Monobodies whereby these residues provide favourable interaction to the epitope surface for the short period of 
phage display screening under strong selection pressure. In agreement with previous  studies36, we also observed 
that higher affinity Affimers (Table 1) expressed less well and CEA-Affimer-I, with the highest affinity expressed 
at much lower levels than CEA-Affimer-II and III.
Figure 5.  Kinetic binding analysis of CEA binding Affimers. Binding of CEA protein was tested at 
concentrations of 7.8 nM-1 μM using twofold dilutions on immobilized Affimer. (A) CEA-Affimer-I; (B) 
CEA-Affimer-II and (C) CEA-Affimer-III. Data were normalized using a double-referencing methods by 
subtracting the responses from an unmodified reference cell and blank injection using running buffer only. 
(D–F) Global fit analysis of the corresponding CEA/Affimer binding data using a simple 1:1 Langmuir binding 
interaction model. The experimental SPR trace (black lines) and theoretical fit (red lines) are overlaid and were 
used to extract the kinetic parameters of the interaction including the association (ka) and dissociation (kd) rate 
constants and equilibrium dissociation constant (KD).
Table 1.  Kinetic values of CEA-Affimer interaction.
Receptor ka ± SE  (M−1 s−1) kd ± SE  (s−1) KD ± SE (nM) χ2
CEA-Affimer-I (2.00 ± 0.84) × 106 (1.29 ± 0.13) × 10–2 6.46 ± 1.38 0.066
CEA-Affimer-II (1.14 ± 0.84) × 106 (1.75 ± 1.08) × 10–2 15.3 ± 0.37 0.049
CEA-Affimer-III (6.78 ± 1.86) × 104 (2.33 ± 0.26) × 10–3 34.4 ± 16 1.94
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Conclusions
This is the first report to demonstrate a novel affinity reagent generated against CEA-derived from a highly stable 
non-immunoglobulin Affimer protein scaffold. The successful results indicate the potential of Affimers to be 
exploited in diagnostic imaging as molecular probes for imaging CEA expressed by tumours. Introduction of 
a single cysteine residue in the C-terminal and  His8-tag region, distant from the antigen binding site provides 
an extra advantage in theranostic applications potentially allowing tumour imaging and delivery of therapeutic 
agents in a single molecule since the Cys thiol group permits easy attachment. Increased expression of CEA in 
serum after tumour resection normally correlates with tumour recurrence and metastasis. The ability of Affimer 
to bind to soluble CEA suggests another use of Affimers as affinity reagents in anti-metastatic therapy. Finally, 
immobilization of biotinylated Affimer onto streptavidin coated chips in SPR analysis demonstrate the possi-
bility of Affimers as biorecognition elements in the fabrication of biosensor devices for CEA detection such as 
electrochemical biosensors for the development of point-of-care devices. A key element for a highly sensitive 
and effective analyte detection with regard to biosensor fabrication is site-directed receptor immobilization. The 
ease of modification via the thiol group at the C-terminal or  his6-tag region facilitate this with Affimer proteins. 
Finally, recent reports have cast doubts on the fidelity of antibody recognition in many  reports37,38 here we show 
a fully validate affinity reagent, including the type of epitope recognised.
Materials and methods
Selection of Affimer proteins by phage display. CEA was sourced from Abcam and was biotinylated 
with a fivefold molar excess of EZ-Link NHS-SS-Biotin (Thermo Scientific) for 1 h at 20 °C and then desalted 
using Zeba Spin Desalting Columns (Thermo Scientific). The success of biotinylation was validated by ELISA 
(Supplementary Fig. S5). Three bio-panning rounds using one standard and two consecutive competitive-bind-
ing pans were carried out to screen for Affimer that bound as previously  described15. Throughout the whole 
panning process, CEA and ySUMO were used as target molecule and positive control, respectively. Panning was 
performed on streptavidin coated wells for 1.5 h at 20 °C on a vibrating platform using the biotinylated CEA and 
ySUMO. Then,  1012 cfu pre-panned phage (phage preincubated in streptavidin-coated wells) were added into 
the biotinylated samples and incubated for another 2 h. Panning wells were then washed 27 times with 300 μl 
of PBST and eluted first with 0.2 M glycine, pH 2.2 for 10 min then neutralized with 1 M Tris–HCl, pH 9.1. A 
second elution followed with 0.1 M triethylamine for 6 min which was then neutralized with 1 M Tris–HCl, pH 
7 prior to infection of ER2738 E. coli cells for 1 h at 37 °C. The infected cells were plated onto LB agar containing 
100 μg/ml carbenicillin and grown overnight at 37 °C. Colonies were scraped and re-cultured in 2TY/100 μg/
ml carbenicillin broth and subsequently infected with approximately 1 × 109 M13K07 helper phage and grown 
overnight with 50 μg/ml of kanamycin at 25 °C and 170 rpm. The second and third pans were performed using 
competitive binding with streptavidin magnetic beads and with NeutrAvidin high binding capacity coated wells, 
respectively to increase the selectivity. The competitive procedure was the same as the first panning except that 
prior to elution of the bound phage, 2.5 µg of non-biotinylated target protein was mixed with 10 × blocking 
buffer, Halt Protease Inhibitor Cocktail and 80% (v/v) glycerol. The mixture was incubated overnight at RT 
washed, eluted and amplified as described above. To screen for positive clones, 48 randomly selected clones 
were tested for specific binding against the target protein via phage ELISA as previously  described15. In brief, the 
phage ELISA was performed by incubating Affimers from the last panning round with or without biotinylated 
CEA. The associated DNA from positive clones were submitted for DNA sequencing analysis to identify the 
range of binders.
Production of Affimer protein and purification. The coding region for selected Affimers was amplified 
by PCR using Forward primer (5′-ATG GCT AGC AAC TCC CTG GAA ATC GAAG) and Reverse primer (5′-TTA 
CTA ATG CGG CCG CAC AAG CGT CAC CAA CCG GTT TG). During amplification, the use of a reverse primer 
containing an additional cysteine codon allowed subsequent generation of protein with a C-terminal cysteine. 
Double digestion with NheI-HF and NotI-HF restriction enzymes at 37 °C for 2 h of the PCR product and engi-
neered pET11a vector were performed prior to ligation and the Affimer proteins were subsequently produced in 
BL21 (DE3) E. coli cells as previously  described15. The cells were harvested, lysed and protein was purified using 
single step chromatography on  Ni2+-NTA affinity resin.
Biotinylation of Affimers. Purified Affimers were biotinylated at the C-terminal cysteine using biotin-
maleimide. Affimer, 150 µl of 40 µM elution solution was mixed with an equal volume of washed Immobilized 
TCEP Disulphide Reducing Gel (Thermo Scientific) for 1 h at 20 °C on a rotator mixer. Freshly reduced Affimer 
was mixed with 27 µl of 2 mM biotin-maleimide and incubation continue for 2 h at 20 °C. Excess biotin was 
removed using Zeba Spin Desalting Columns.
Pull-down assays. Twenty micrograms of purified Affimer were dialysed in 1 × PBS prior incubated with 
40 µl of washed  Ni2+ -NTA slurry for 90 min at 4 °C on a rotator. Affimer-loaded resins were washed once with 
1 × PBS and mixed with purified CEA from Abcam, cell lysates from LoVo cells, CEA secreted into the medium 
or deglycosylated CEA after treatment with PNGase F. These mixtures were incubated overnight at 4 °C on a 
tube rotator. The resins were washed three times with 1 × PBS before resuspending in SDS sample buffer. SDS-
PAGE and western blot analysis were conducted to determine the success of the pull-down assay.
Affinity and immunofluorescence staining of CEA on LoVo cells. LoVo (ATCC-CCL229), a cell 
line that positively expresses CEA, was grown in F-12 Nutrient Mixture containing GlutaMAX-I supplemented 
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with 10% (v/v) heat-inactivated foetal bovine serum, 50 U/ml of penicillin and 50 µg/ml of streptomycin at 37 °C 
under 5%  CO2 humidity conditions. Culture medium was aspirated every 3 days and collected for CEA protein 
isolation, whilst the cells continued to grow as monolayer cultures until reaching confluency at 7 day in a 150 
 cm2 flask. Meanwhile, the HEK 293 (ATCC-CRL-1573), cell line that does not express CEA protein was grown 
in DMEM containing GlutaMAX-I supplemented with 10% (v/v) heat-inactivated foetal bovine serum.
To determine the specificity of Affimer binding to CEA protein, fluorescence staining of fixed cells was 
investigated. The cells were seeded at 3 × 105/well on cover slips in 6-well plates until they reached about 70% 
confluency. The medium was discarded, followed by three times washing in PBS (pH7.4) and subsequent fixation 
in 4% (w/v) paraformaldehyde solution for 10 min at 20 °C. The fixed cells were washed again three times in 
PBS and blocked for 30 min at 20 °C in SuperBlock T20 (TBS) blocking buffer, pH7.4 (Thermo Scientific). Cells 
were incubated overnight at 4 °C with 10 µg/ml of biotinylated Affimer diluted in blocking buffer. Then, 1 µg/
ml of mouse anti-human IgG CEA monoclonal antibody (MA5-14675, Thermo Scientific) was used as primary 
antibody and included as the positive control on separate coverslips. After overnight incubation, the coverslips 
were washed again three times with PBS and incubated with secondary detection reagents. Goat anti-mouse 
IgG conjugated with Alexa Fluor 488 (Invitrogen) and Streptavidin DyLight 488 conjugate were applied to cells 
probed with primary monoclonal antibody and biotinylated Affimer, respectively. The secondary detection rea-
gent was diluted to 1 µg/ml in blocking buffer and incubated with the labelled cells for 1 h at 20 °C in the dark. 
Coverslips were repeatedly washed with PBS for three times and mounted with ProLong Gold Antifade reagent 
with DAPI present to label the nuclei. Primary antibody or biotinylated Affimer were omitted in the negative 
control samples. CEA protein localization was visualized using an Axio Observer Z1 microscope equipped with 
an Apotome system of structured illumination (Zeiss, Germany).
Isolation of crude CEA protein. The collected medium was centrifuged at 3220×g for 5 min at 4 °C to 
remove cell debris. The supernatant was then concentrated using Amicon Ultra Centrifugal Filters (15 ml, 50 
KDa cut-off, Millipore) for another 10 min at 5000×g and 4 °C prior to protein extraction. Once cells reached 
confluency, medium was discarded and cells were washed once with 1 × ice-cold Dulbecco’s PBS. Protein was 
extracted from LoVo cells and HEK 293 cells by lysis in 1 ml of mammalian cell PE LB lysis buffer (G-Bio-
sciences) containing 10 µl of 100 × Mammalian ProteaseArrest inhibitor cocktail (G-Biosciences) and incubated 
for 10 min at 4 °C. Cell lysates were then centrifuged at 16,000×g for 30 min at 4 °C and stored at -80 °C until 
further analysis.
Deglycosylation of CEA protein using PNGase F. Deglycosylation of CEA protein using PNGase F 
was performed under denaturing conditions. RNase B protein was used as a positive control for PNGase F treat-
ment. Generally, 20 µg of purified CEA or RNase B was heat denatured at 100 °C for 10 min in 1 × glycoprotein 
denaturing buffer (0.5% SDS, 40 mM DTT) according to the manufacturer’s protocol (New England BioLabs 
Inc). Samples were subsequently treated with 500 U/µl of PNGase F in 1 × GlycoBuffer 2 and 1% (v/v) NP-40 and 
incubated for 1 h at 37 °C. The extent of deglycosylation was visualized via SDS-PAGE and the deglycosylated 
protein was subsequently used for pull-down assays.
Immunoblotting. Identification of CEA present in the cell lysates, protein secreted into the media and 
deglycosylated samples were investigated by immunoblotting. Proteins were separated via SDS-PAGE and trans-
ferred onto 0.2 µm pore PVDF membranes by applying a constant voltage of 100 V for 90 min with cooling. 
Membranes were blocked for 30 min in SuperBlock T20 (TBS) blocking solution and washed three times with 
0.1% (v/v) TBST and subsequently probed with appropriate detection agents. These were either anti-CEA mono-
clonal antibody or anti-His6 tag-HRP conjugated antibody diluted to 1:1000 in blocking solution and incubated 
for 1 h at RT. For the membrane probed with anti-CEA monoclonal antibody, incubation of secondary HRP-
conjugated antibody (1:2000) was performed for 1 h at 20 °C prior to the final washes. Three final washes were 
performed in 0.1% (v/v) TBST followed by three washes in 1xTBS before adding ECL substrate and imaging 
using a Syngene G:BOX imager.
SPR analysis of Affimer binding kinetics. Kinetic binding analysis was conducted using a BIACore 3000 
instrument (GE Healthcare, Sweden). The instrument temperature was set at 25 °C throughout the experiments 
and was cleaned by priming with running buffer containing 1 × PBS supplemented with 0.1% (v/v) Triton-X-100. 
A new streptavidin (SA) sensor chip (GE Healthcare, Sweden) was preconditioned by injecting 1 M NaCl and 
50 mM NaOH at a flow rate of 40 µl/min prior to immobilization of biotinylated Affimer. Three flow cells (flow 
cell 2 to 4) were used to immobilize a low-density surface (230–270 RU) at a flow rate of 5 µl/min using 10 nM 
of biotinylated Affimer-CEA-I, II and III, respectively. Flow cell 1 was kept unmodified and used as a reference 
cell. CEA analyte was prepared in concentrations from 1 µM to 7.81 nM via twofold serial dilutions. Running 
buffer was flowed over the flow cells to equilibrate them prior to a succession of injections of CEA at increasing 
concentrations using a flow rate of 50 µl/min for 3 min. The dissociation rate of the CEA/Affimer complex was 
then monitored for 5 min followed by surface regeneration via injecting 1 × PBS containing 1 M NaCl for 4 min 
before injecting the subsequent CEA concentration. Experiments were done in triplicate. Data were normalized 
using a double-referencing methods by subtracting the responses from an unmodified reference cell and blank 
injection using running buffer only. Kinetic binding analysis was carried out using BIAevaluation software ver-
sion 3.2 using a simple 1:1 Langmuir binding interaction model to determine the association and dissociation 
rate constants (ka and kd, respectively) and equilibrium dissociation constant (KD). These analyses are based on a 
combination of numerical integration and non-linear least-squares global curve fitting as previously  described39.
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